Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02568449 · OUTCOME

Progression-free Survival (PFS)

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent · Source last updated 2021-12-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 4 months

What was measured

PFS will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).

Groups in this outcome

Treatment (Nintedanib)

Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Nintedanib)20

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Nintedanib)1.8Not reported1.53.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.5
        upper Limit
        3.5
        value
        1.8
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
PFS will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months).
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Nintedanib: Given PO
    id
    OG000
    title
    Treatment (Nintedanib)
param Type
MEDIAN
reporting Status
POSTED
time Frame
From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 4 months
title
Progression-free Survival (PFS)
type
PRIMARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice